Related Experiment Video
Updated: Jun 21, 2026
09:44
Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery
Published on: September 26, 2025
Biocompatible ionic liquids: a new approach for stabilizing proteins in liquid formulation.
Regina M Vrikkis1, Kevin J Fraser, Kyoko Fujita
1Department of Mechanical Engineering, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte, NC 28223, USA. rmkemp@uncc.edu
Journal of Biomechanical Engineering
|July 31, 2009
Summary
Ionic liquids (ILs) show promise for stabilizing therapeutic proteins. Biocompatible ILs, like choline dihydrogen phosphate (choline dhp), demonstrated low cytotoxicity and enhanced protein stability, suggesting potential for drug formulation.
Area of Science:
- Biochemistry
- Materials Science
- Pharmacology
Background:
- Ionic liquids (ILs) offer potential for stabilizing proteins in therapeutic formulations.
- Assessing the biocompatibility of ILs is crucial for clinical translation.
- Protein-based drugs are a growing area in modern medicine.
Purpose of the Study:
- To investigate the cytotoxicity of rationally synthesized ILs.
- To evaluate the protein-stabilizing capabilities of specific ILs.
- To explore the potential of biocompatible ILs in liquid drug formulations.
Main Methods:
- Cytotoxicity assessed using resazurin reduction assay on J774 macrophage cell line.
- Protein structural stability evaluated using differential scanning microcalorimetry (DSC).
- Functional activity of lysozyme assessed via Micrococcus lysodiekticus activity test.
Main Results:
- Toxicity order found to be choline dihydrogen phosphate (choline dhp) < choline saccharinate < 1-butyl 3-methyl imidazolium lactate (bmim lactate).
- Lysozyme stored in 80 wt% choline dhp (aq) showed higher activity and folded fraction after 1 month compared to aqueous buffer controls.
- All tested ILs exhibited relatively benign biocompatibility profiles.
Conclusions:
- Biocompatibility and protein stabilization can be rationally designed into ILs.
- Choline dhp demonstrates potential as a stabilizing and biocompatible solvent for therapeutic proteins.
- These findings support the development of ILs for advanced protein-based drug formulations.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:29The Colloidal State
The formation of a colloidal system is exemplified by an aqueous solution containing Cl− ions is introduced to another containing Ag+ ions, resulting in the precipitation of solid AgCl as extremely tiny crystals. Instead of settling out as a filterable precipitate, these crystals remain suspended in the liquid, showcasing a colloidal system.A colloidal system involves colloidal particles within the approximate range of 1 to 1000 nm in at least one dimension, dispersed in a medium called the...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...